Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2026 Earnings Call Transcript May 12, 2026
Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.22 EPS, expectations were $-0.18.
Operator: Good afternoon, and welcome to Relmada Therapeutics First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this conference call is being recorded. And will be available for replay on the Realmada website. I would now like to...
